These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 22884766

  • 1. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R, Leister C, El Gaaloul M, Chalon S, Sonnichsen D.
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [Abstract] [Full Text] [Related]

  • 2. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
    Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D.
    J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
    [Abstract] [Full Text] [Related]

  • 3. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, Sonnichsen D.
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
    Abbas R, Hug BA, Leister C, Sonnichsen D.
    Int J Cancer; 2012 Aug 01; 131(3):E304-11. PubMed ID: 22065400
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
    Abbas R, Chalon S, Leister C, El Gaaloul M, Sonnichsen D.
    Cancer Chemother Pharmacol; 2013 Jan 01; 71(1):123-32. PubMed ID: 23053269
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib.
    Abbas R, Hsyu PH.
    Clin Pharmacokinet; 2016 Oct 01; 55(10):1191-1204. PubMed ID: 27113346
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
    Li J, Kankam M, Trone D, Gammon G.
    Br J Clin Pharmacol; 2019 Sep 01; 85(9):2108-2117. PubMed ID: 31173645
    [Abstract] [Full Text] [Related]

  • 19. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
    Derks M, Fowler S, Kuhlmann O.
    Clin Ther; 2009 Mar 01; 31(3):586-99. PubMed ID: 19393849
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.